Management of the nephrotic syndrome.
D000284:Administration, Oral; D000328:Adult; D000367:Age Factors; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004338:Drug Combinations; D005921:Glomerulonephritis / Q000150:complications; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000175:diagnosis; D008055:Lipids / Q000097:blood; D008134:Long-Term Care; D009393:Nephritis / Q000150:complications; D009404:Nephrotic Syndrome / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D010357:Patient Isolators; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012082:Renal Veins; D013924:Thrombophlebitis / Q000150:complications
D004338:Drug Combinations; D007166:Immunosuppressive Agents; D008055:Lipids; D003520:Cyclophosphamide; D011241:Prednisone